disitamab vedotin + tislelizumab

Disitamab Vedotin + Tislelizumab is a combination therapy consisting of an antibody-drug conjugate (Disitamab Vedotin) and a PD-1 inhibitor (Tislelizumab). Disitamab Vedotin (RC48-ADC) is a humanized anti-HER2 antibody conjugated with monomethyl auristatin E (MMAE) via a cleavable peptide linker. It works through multiple mechanisms including MMAE-mediated direct cytotoxicity, bystander effect, and immunogenic cell death. Tislelizumab is a PD-1 inhibitor that enhances immune response against cancer cells. The combination has shown promising efficacy in urothelial carcinoma, particularly in patients with HER2 expression, with objective response rates ranging from 62.5% to 83.3% in various studies.

Brand names

Tevimbratislelizumab-jsgr

Other names

DV + tislelizumabDisitamab Vedotin combined with Tislelizumab